Vir Biotechnology, Inc.

NasdaqGS:VIR Stock Report

Market Cap: US$702.9m

Vir Biotechnology Future Growth

Future criteria checks 2/6

Vir Biotechnology is forecast to grow earnings and revenue by 16.3% and 58.1% per annum respectively. EPS is expected to grow by 24.7% per annum. Return on equity is forecast to be -60.2% in 3 years.

Key information

16.3%

Earnings growth rate

24.7%

EPS growth rate

Biotechs earnings growth24.0%
Revenue growth rate58.1%
Future return on equity-60.2%
Analyst coverage

Good

Last updated09 May 2025

Recent future growth updates

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

May 11
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Nov 04
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Recent updates

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

May 11
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment

May 08
author-image

Strong Clinical Advances In Oncology And Hepatitis Delta Will Secure Future Success

Mar 23 ECLIPSE Phase III program in hepatitis delta and oncology advancements promise revenue and earnings growth through new treatments and diversified revenue streams.

Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology

Mar 04

Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?

Jan 09

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Invest In Growth?

Jan 07
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Invest In Growth?

Vir Biotechnology Could Be An Early Riser In 2025 With Oncology Data In January

Dec 13

Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off

Nov 05

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Nov 04
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Trimming Their Forecasts

Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

Sep 08
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans?

Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Aug 03
Analysts Are Updating Their Vir Biotechnology, Inc. (NASDAQ:VIR) Estimates After Its Second-Quarter Results

Bullish On Vir Biotechnology's Innovative Pipeline That Targets HIV And Hepatitis

Jul 17

Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

May 05
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

Vir Biotechnology Provides Some Hope For Its Beleaguered Shareholders

May 03

Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta

Feb 28

Sticking With Vir Biotechnology

Jan 17

Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Aug 07
Vir Biotechnology, Inc. (NASDAQ:VIR) Analysts Just Slashed This Year's Revenue Estimates By 37%

Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Jul 24
Revenues Working Against Vir Biotechnology, Inc.'s (NASDAQ:VIR) Share Price Following 42% Dive

Earnings and Revenue Growth Forecasts

NasdaqGS:VIR - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202750-517-501-4577
12/31/202626-526-463-4278
12/31/202519-493-373-2646
3/31/202521-578-422-415N/A
12/31/202474-522-454-446N/A
9/30/202479-533-473-467N/A
6/30/202479-483-459-451N/A
3/31/202480-539-779-762N/A
12/31/202386-615-800-779N/A
9/30/2023119-601-668-636N/A
6/30/2023491-262-410-362N/A
3/31/2023446-144928987N/A
12/31/20221,6165161,5951,663N/A
9/30/20222,3791,1431,5671,636N/A
6/30/20222,1081,0781,3571,412N/A
3/31/20222,3261,216555592N/A
12/31/20211,095529-69-48N/A
9/30/2021284-102-149-137N/A
6/30/2021183-297-88-81N/A
3/31/202173-390-238-232N/A
12/31/202076-299-197-191N/A
9/30/202076-257-153-148N/A
6/30/202075-220-140-135N/A
3/31/202010-223-155-149N/A
12/31/20198-175-139-130N/A
9/30/201910-137-130-120N/A
6/30/201912-122-128-118N/A
3/31/201912-117-119-109N/A
12/31/201811-116N/A-94N/A
12/31/20173-70N/A-66N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: VIR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VIR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VIR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VIR's revenue (58.1% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: VIR's revenue (58.1% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: VIR is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/11 17:08
End of Day Share Price 2025/05/09 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Vir Biotechnology, Inc. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Huidong WangBarclays
Alec StranahanBofA Global Research